TLR10

Across TCGA pan-cancer cohorts, TLR10 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TLR10 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TLR10 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TLR10 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BLCA, UCEC, and SARC are the cancer types where TLR10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.861	0.323	.018	10	view →
UCEC	DFS	Median	All	0.918	0.619	.015	8	view →
SARC	DFS	Median	All	0.065	0.632	<.001	3	view →
GBM	DFS	Median	All	0.074	0.244	.016	3	view →
LUSC	DFS	Median	All	0.064	0.791	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TLR10–BLCA (DFS)

Open the BLCA breakdown →